Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapy

Clinical and Applied Thrombosis/Hemostasis

Volumn 14, Issue 1, 2008, Pages 29-37

  Redman, Andrea R ^a   Zheng, Jack ^b   Shamsi, Shahab A ^b   Huo, Jingguo ^d   Kelly, Edward J ^e   Ho, Rodney J Y ^e   Ritchie, Denise M ^c   Yuen Yi Hon, ^f  

^a Rockdale Medical Center   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d EAST TEXAS MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cytochrome P 450 enzyme system; Genetic polymorphisms; R warfarin concentrations; S warfarin concentrations; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

AGED; ANTICOAGULATION; ARTICLE; CAPILLARY ELECTROCHROMATOGRAPHY; CHI SQUARE TEST; CLINICAL ARTICLE; CONFIDENCE INTERVAL; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; FISHER EXACT TEST; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; RANK SUM TEST; RISK; STATISTICAL SIGNIFICANCE;

AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; STEREOISOMERISM; VARIATION (GENETICS); WARFARIN;

EID: 37549033937     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607304403     Document Type: Article

References (31)

1. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 ; 126: 204S - 233S.
2. Chan E., McLachlan AJ, Pegg M., MacKay AD, Cole RB, Rowland M. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with racwarfarin. Br J Clin Pharmacol. 1994 ; 37: 563-569.
3. Henne KR, Gaedigk A., Gupta G., Leeder JS, Rettie AE Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J Chromatogr B. 1998 ; 710: 143-148.
4. Miners JO, Birkett DJ Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clinical Pharmacol. 1998 ; 45: 525-538.
5. Kaminsky LS, Zhang Z-Y. Human P450 metabolism of warfarin. Pharmacol Ther. 1997 ; 73: 67-74.
6. Lee CR, Goldstein JA, Pieper JA Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002 ; 12: 251-263.
7. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 1994 ; 4: 39-42.
8. Rettie AE, Haining RL, Bajpai M., Levy RH A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res. 1999 ; 35: 253-255.
9. Steward DJ, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 1997 ; 7: 361-367.
10. Dickmann LJ, Rettie AE, Kneller MB, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol. 2001 ; 60: 382-387.
11. Goldstein JA Polymorphisms in the human CYP2C subfamily. Drug Metab Rev. 2002 ; 34: 5.
12. Imai J., Ieiri I., Mamiya K., et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene. Pharmacogenetics. 2000 ; 10: 85-89.
13. Kidd RS, Curry TB, Gallagher S., Edeki T., Blaisdell J., Goldstein J. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001 ; 11: 803-808.
14. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002 ; 287: 1690-1698.
15. Sachse C., Brockmoller J., Bauer S., Roots I. Functional significance of a C-> A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999 ; 47: 445-449.
16. Redman AR, Dickmann LJ, Kidd RS, Goldstein JA, Ritchie DM, Hon YY CYP2C9 genetic polymorphisms and warfarin. Clin Appl Thromb Hemost. 2004 ; 10: 149-154.
17. Zheng J., Norton D., Shamsi SA Fabrication of internally tapered capillaries for capillary electrochromatography electrospray ionization mass spectrometry. Anal Chem. 2006 ; 78: 1323-1330.
18. Zheng J., Shamsi SA Combination of chiral capillary electrochromatography with electrospray ionization mass spectrometry: method development and assay of warfarin enantiomers in human plasma. Anal Chem. 2003 ; 75: 6295-6305.
19. Aithal GP, Day CP, Kesteven PJ, Daly AK Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999 ; 353: 717-719.
20. Scordo MG, Pengo V., Spina E., Dahl ML, Gusella M., Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther. 2002 ; 72: 702-710.
21. Takahashi H., Kashima T., Nomizo Y., Muramoto N., Shimizu T. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmaol Ther. 1998 ; 63: 519-528.
22. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Int Med. 1996 ; 124: 970-979.
23. Kamali F., Khan TI, King BP, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther. 2004 ; 75: 204-212.
24. Takahashi H., Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics. 2006 ; 16: 101-110.
25. Yasar U., Aklillu E., Canaparo R., et al. Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations. Eur J Clin Pharmacol. 2002 ; 58: 555-558.
26. Allabi AC, Gala JL, Horsmans Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 ; 15: 779-786.
27. Allabi AC, Gala JL, Horsmans Y., et al. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmaol Ther. 2004 ; 76: 113-118.
28. Gage BF, Milligan PE, Banet GA, Duncan JR, McLeod HL Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost. 2004 ; 91: 87-94.
29. Joffe HV, Xu R., Johnson FB, Longtine J., Kucher N., Goldhaber SZ Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost. 2004 ; 91: 1123-1128.
30. Takahashi H., Wilkinson GR, Caraco Y., et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmaol Ther. 2003 ; 73: 253-263.
31. Nakajima M., Yokoi T., Mizutani M., et al. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem. 1999 ; 125: 803-808.